ENTA
Enanta Pharmaceuticals, Inc.
ENTA has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ENTA overall, supported by stronger fundamentals and stronger modeled upside.
ENTA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
ENTA's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ENTA PE Valuation
ENTA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ENTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect ENTA's losses to shrink, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ENTA on the outlook, with more favorable revenue expectations.
ENTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.42 | +$1.90 |
| Q1 2026 | -$2.60 | +$1.94 |
| Q4 2025 | -$3.21 | +$1.74 |
| Q3 2025 | -$3.84 | +$1.64 |
| Q2 2025 | -$4.32 | +$1.14 |
| Q1 2025 | -$4.54 | +$1.71 |
| Q4 2024 | -$4.95 | +$1.62 |
| Q3 2024 | -$5.48 | +$0.90 |
ENTA is still losing money, but far less than before: $2.42 per share over the past year, against $6.57 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ENTA on earnings quality, reporting a profit while its opponent remains loss making.
ENTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $14.4M | -22% |
| Q1 2026 | $17.2M | +15% |
| Q4 2025 | $18.6M | +9.8% |
| Q3 2025 | $15.1M | +3.5% |
| Q2 2025 | $18.3M | +1.9% |
| Q1 2025 | $14.9M | -12% |
| Q4 2024 | $17M | -5.8% |
| Q3 2024 | $14.6M | -23% |
ENTA's revenue fell from its 2019 peak and has held roughly level since: $14M last quarter, down 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -120% | -17 points |
| Q1 2026 | -69% | +95 points |
| Q4 2025 | -60% | +78 points |
| Q3 2025 | -122% | +83 points |
| Q2 2025 | -103% | +31 points |
| Q1 2025 | -164% | +28 points |
| Q4 2024 | -139% | +55 points |
| Q3 2024 | -204% | -41 points |
ENTA's operating margin was −120% last quarter, down 17 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ENTA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ENTA on profitability, with a higher operating margin.
ENTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10M | -158% |
| Q1 2026 | -$7.2M | +$8.9M |
| Q4 2025 | -$11.8M | +$13.7M |
| Q3 2025 | -$7.9M | +$11.4M |
| Q2 2025 | $17.4M | +$38.7M |
| Q1 2025 | -$16M | +$14.2M |
| Q4 2024 | -$25.5M | +$229K |
| Q3 2024 | -$19.4M | +$3.6M |
ENTA has burned cash in almost every quarter: −$37M over the past year, against −$44M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ENTA on cash generation, producing positive trailing cash flow while its opponent burns cash.
ENTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +50K shares |
| 1 year | +36% | +7.7M shares |
| 3 years | +40% | +8.4M shares |
| 5 years | +45% | +9.1M shares |
ENTA has 29M diluted shares, up 36% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over ENTA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ENTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -5.0x | Net Cash |
| Q4 2019 | -1.1x | Net Cash |
| Q3 2019 | -1.3x | Net Cash |
ENTA has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ENTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.1 | Neutral |
| Stochastic | 14.2 | Oversold |
ENTA's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ENTA PE vs Healthcare Sector
| Metric | ENTA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ENTA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ENTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.6 | 3.6% below |
| 20 week MA | $12.7 | 12% below |
| 50 week MA | $13.3 | 15% below |
| 100 week MA | $10.4 | 7.8% above |
| 200 week MA | $14.5 | 23% below |
ENTA's trend is mixed: it's above one of its five weekly moving averages, and 23% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ENTA on trend strength, trading above more of its moving averages.
ENTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.5 | $42.9 | -31% |
| 2021 | $42.9 | $76.4 | +78% |
| 2022 | $76.4 | $47.1 | -38% |
| 2023 | $47.1 | $9.41 | -80% |
| 2024 | $9.41 | $6.01 | -36% |
| 2025 | $6.01 | $16.9 | +180% |
| 2026 YTD | $16.9 | $11.2 | -34% |
ENTA's yearly returns have swung widely, from +180% in 2025 to −80% in 2023. It's down 34% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ENTA on returns for 2026, with the stronger performance.